PlumBot: Bot: Creating new article from JSON

2026-03-14T15:56:25Z

Bot: Creating new article from JSON

New page

💊 '''Brand-name drug''' refers to a pharmaceutical product marketed under a proprietary trade name by the manufacturer that originally developed it, as distinct from its [[Definition:Generic drug | generic]] equivalent. In the insurance context, brand-name drugs are a central cost driver in [[Definition:Health insurance | health insurance]], [[Definition:Pharmacy benefit management (PBM) | pharmacy benefit management]], and [[Definition:Workers' compensation insurance | workers' compensation]] programs worldwide. Because these medications carry patent protection and premium pricing, they significantly influence [[Definition:Claims cost | claims costs]], [[Definition:Loss ratio (L/R) | loss ratios]], and the design of [[Definition:Formulary | formularies]] that insurers and benefit managers use to control pharmaceutical spending.

⚙️ When a policyholder fills a prescription for a brand-name drug, the [[Definition:Insurance carrier | insurer]] or its [[Definition:Third-party administrator (TPA) | third-party administrator]] processes the claim against the applicable [[Definition:Benefit schedule | benefit schedule]], which typically assigns brand-name medications to a higher [[Definition:Cost-sharing | cost-sharing]] tier than generics. Many health insurers negotiate rebates and discounts with pharmaceutical manufacturers through [[Definition:Pharmacy benefit management (PBM) | PBMs]], aiming to offset the elevated list prices. In markets such as the United States, tiered [[Definition:Copayment | copayment]] structures and [[Definition:Prior authorization | prior authorization]] requirements steer members toward lower-cost alternatives. In jurisdictions with national health systems — the United Kingdom's NHS, for example, or Japan's universal coverage framework — government pricing controls and reimbursement schedules interact with private supplemental [[Definition:Health insurance | health insurance]] to shape how brand-name drug costs flow through insurer portfolios.

📈 The financial impact of brand-name drugs on insurers extends well beyond individual claim payments. Specialty brand-name therapies — particularly biologics and oncology treatments — have become one of the fastest-growing segments of insured medical expense globally, pressuring [[Definition:Medical loss ratio (MLR) | medical loss ratios]] and forcing [[Definition:Actuarial analysis | actuarial]] reassessments of trend assumptions. Insurers and [[Definition:Reinsurer | reinsurers]] writing [[Definition:Stop-loss insurance | stop-loss]] or [[Definition:Excess of loss reinsurance | excess-of-loss]] layers above employer-sponsored health plans must model brand-name drug trend with increasing sophistication, as a single high-cost therapy can breach attachment points that were historically adequate. The rise of [[Definition:Insurtech | insurtech]] platforms offering real-time drug-cost transparency and AI-driven [[Definition:Utilization management | utilization management]] reflects the industry's urgent need to manage this exposure more effectively.

'''Related concepts:'''
{{Div col|colwidth=20em}}
* [[Definition:Generic drug]]
* [[Definition:Formulary]]
* [[Definition:Pharmacy benefit management (PBM)]]
* [[Definition:Health insurance]]
* [[Definition:Medical loss ratio (MLR)]]
* [[Definition:Prior authorization]]
{{Div col end}}

Definition:Brand-name drug - Revision history

PlumBot: Bot: Creating new article from JSON